Longitudinal clinical experience can add information that short trials cannot, but continued treatment is not a randomized measure of efficacy. This cohort followed afamelanotide use in erythropoietic protoporphyria. Primary study
Cohort findings
The report described 115 patients at two centers, with treatment experience extending up to eight years. Disease-specific quality-of-life scores improved and remained higher during observation. Discontinuation included reasons unrelated to perceived efficacy, such as pregnancy and financial constraints. Attributed adverse events were predominantly minor. Primary report
Our appraisal: maximum follow-up is not everyone's follow-up
“Up to eight years” does not mean that all participants were observed for eight years. A useful safety account should describe the distribution of exposure, total observation time, and completeness of follow-up. Rare-event interpretation depends on those quantities.
Treatment retention is influenced by benefit, tolerability, access, cost, and personal circumstances. A discontinuation rate cannot be interpreted as a pure efficacy measure without examining its reasons. Conversely, a financial discontinuation should not be labeled treatment failure.
Repeated quality-of-life scores offer valuable patient-centered information, but an uncontrolled before-and-during comparison remains vulnerable to selection, expectation, and changing exposure to light. Patients who remain on treatment may differ from those who leave observation.
The cohort may also overlap earlier clinical-development populations. Its contribution is extended follow-up and routine-care experience, not necessarily a wholly independent set of participants. A synthesis should check study lineage before adding patient counts across publications.
This report supports a real-world evidence discussion in a specific rare disease. It does not establish that all adverse effects are known or that research-market Melanotan I products share the same benefit–risk profile. Full review should retain exposure duration, monitoring procedures, attrition, and the disease-specific nature of the quality-of-life instrument.
Frequently asked questions
Was this a randomized long-term trial?
No; it was observational.
Did every patient have eight years of follow-up?
That is not what “up to” means.
Did every discontinuation indicate lack of benefit?
No.
Is retention a pure efficacy measure?
No.
Were quality-of-life outcomes reported?
Yes.
Can related publications contain overlapping patients?
Yes; lineage must be checked.
What makes long-term safety reporting useful?
Transparent exposure time, monitoring, events, and completeness of follow-up.